Fu J, Zhang W, Jin S
Cancer Institute (Hospital), Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing.
Zhonghua Zhong Liu Za Zhi. 1998 Nov;20(6):434-6.
To investigate the possibility of using telomerase as a tumor marker for human primary hepatocellular carcinomas (HCC).
Human liver specimens, comprising 33 HCC and adjacent peritumoral tissues, 4 hepatic metastases and the adjacent peritumoral tissues, 6 benign liver lesions and 6 normal liver tissues, were examined for telomerase activity by TRAP assay based on PCR.
Thirty of 33 HCC and 9 of 33 adjacent tissue specimens were positive for telomerase activity with a positive rate of 90.9% and 27.3%, respectively. Four hepatic metastatic cancer and 2 adjacent tissues were positive. Telomerase activity was negative in 6 nomal liver tissues and 5 of 6 benign liver lesions. There was no correlation between the clinical stage of HCC and their telomerase activity.
Positive telomerase activity occurs in the majority of HCC examined. It can be used as a tumor marker in the diagnosis of HCC.
探讨将端粒酶用作人类原发性肝细胞癌（HCC）肿瘤标志物的可能性。
采用基于PCR的TRAP分析法检测了人类肝脏标本的端粒酶活性，这些标本包括33例HCC及其癌旁组织、4例肝转移癌及其癌旁组织、6例良性肝病变组织和6例正常肝组织。
33例HCC标本中有30例端粒酶活性呈阳性，33例癌旁组织标本中有9例呈阳性，阳性率分别为90.9%和27.3%。4例肝转移癌及2例癌旁组织呈阳性。6例正常肝组织和6例良性肝病变组织中的5例端粒酶活性为阴性。HCC的临床分期与其端粒酶活性之间无相关性。
在所检测的大多数HCC中出现端粒酶活性阳性。它可作为HCC诊断中的一种肿瘤标志物。
Zotero 插件